Jonathan Kay to Contrast Media
This is a "connection" page, showing publications Jonathan Kay has written about Contrast Media.
Connection Strength
3.378
-
Todd DJ, Kay J. Gadolinium-Induced Fibrosis. Annu Rev Med. 2016; 67:273-91.
Score: 0.425
-
Schmidt-Lauber C, Bossaller L, Abujudeh HH, Vladimer GI, Christ A, Fitzgerald KA, Latz E, Gravallese EM, Marshak-Rothstein A, Kay J. Gadolinium-based compounds induce NLRP3-dependent IL-1? production and peritoneal inflammation. Ann Rheum Dis. 2015 Nov; 74(11):2062-9.
Score: 0.381
-
Lima XT, Alora-Palli MB, Kimball AB, Kay J. Validation of a screening instrument for nephrogenic systemic fibrosis. Arthritis Care Res (Hoboken). 2013 Apr; 65(4):637-42.
Score: 0.351
-
Bernstein EJ, Schmidt-Lauber C, Kay J. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. Best Pract Res Clin Rheumatol. 2012 Aug; 26(4):489-503.
Score: 0.335
-
Kay J, Czirj?k L. Gadolinium and systemic fibrosis: guilt by association. Ann Rheum Dis. 2010 Nov; 69(11):1895-7.
Score: 0.297
-
Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. Radiology. 2009 Oct; 253(1):81-9.
Score: 0.274
-
Kay J. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis. 2008 Dec; 67 Suppl 3:iii66-9.
Score: 0.260
-
Todd DJ, Kay J. Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Curr Rheumatol Rep. 2008 Jul; 10(3):195-204.
Score: 0.253
-
Kay J. Gadolinium and nephrogenic systemic fibrosis: the evidence of things not seen. Cleve Clin J Med. 2008 Feb; 75(2):112, 114, 117.
Score: 0.245
-
Todd DJ, Kagan A, Chibnik LB, Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum. 2007 Oct; 56(10):3433-41.
Score: 0.240
-
Bernstein EJ, Isakova T, Sullivan ME, Chibnik LB, Wolf M, Kay J. Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. Rheumatology (Oxford). 2014 Sep; 53(9):1613-7.
Score: 0.094
-
Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014 Jul; 69(7):661-8.
Score: 0.093
-
Abujudeh HH, Rolls H, Kaewlai R, Agarwal S, Gebreananya ZA, Saini S, Schaefer PW, Kay J. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging. 2009 Dec; 30(6):1335-40.
Score: 0.070
-
Le LP, Garibyan L, Lara D, Finberg KE, Iafrate AJ, Duncan LM, Kay J, Nazarian RM. Fibrosis-associated single-nucleotide polymorphisms in TGFB1 and CAV1 are not associated with the development of nephrogenic systemic fibrosis. Am J Dermatopathol. 2013 May; 35(3):351-6.
Score: 0.022
-
Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology. 2011 Jul; 260(1):105-11.
Score: 0.019
-
Nazarian RM, Mandal RV, Kagan A, Kay J, Duncan LM. Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid. J Am Acad Dermatol. 2011 Apr; 64(4):741-7.
Score: 0.019